Top

Osteoporosis International

Published in:

Open Access 01-05-2008 | Original Article

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

Authors: E. S. Siris, J. A. Simon, I. P. Barton, M. R. McClung, A. Grauer

Published in: Osteoporosis International | Issue 5/2008

Abstract

Summary

This posthoc analysis of four trials studied the efficacy of risedronate to reduce fragility fractures in postmenopausal women with osteopenia (i.e., T-scores between −1 and −2.5). Risedronate reduced the fracture risk by 73% (p = 0.023) in this population of women with low femoral neck bone mass and no prevalent vertebral fractures.

Introduction

Low bone mass represents an increasing health risk and burden. Half of fragility fractures occur in osteopenic women underscoring the need for treatments reducing fracture risk. This analysis reports the effect of risedronate to reduce fragility fracture risk in osteopenic women without prevalent vertebral fractures.

Methods

Postmenopausal women with osteopenia, defined as femoral neck T-score between −1 and −2.5 by DXA and no prevalent vertebral fractures, were identified from four controlled randomized trials (BMD Multinational, BMD North America, VERT Multinational and VERT North America). The risk reduction for fragility fractures in patients receiving 5 mg risedronate daily for 1.5 to 3 years compared to placebo was assessed. An additional sensitivity analysis excluded patients who were osteopenic at the femoral neck but had a BMD lower than −2.5 SD at the lumbar spine.

Results

Six hundred and twenty postmenopausal women with osteopenia were included, receiving either placebo (n = 309) or risedronate 5 mg (n = 311). Risedronate reduced the risk of fragility fractures by 73% over 3 years versus placebo (p = 0.023); cumulative fragility fracture incidence was 6.9% in placebo-treated versus 2.2% in risedronate-treated patients. The magnitude of the effect was similar in the sensitivity analysis subset.

Conclusion

Risedronate significantly reduced the risk of fragility fractures in postmenopausal women with osteopenia (femoral neck T-score between −1 and −2.5 SD) and no prevalent vertebral fractures.

Siris ES, Miller PD, Barrett-Connor E et al (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822PubMedCrossRef

Schuit SC, van der Klift M, Weel AE et al (2004) Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34:195–202PubMedCrossRef

Wainwright SA, Marshall LM, Ensrud KE et al (2005) Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 90:2787–2793PubMedCrossRef

Sornay-Rendu E, Munoz F, Garnero P et al (2005) Identification of osteopenic women at high risk of fracture: the OFELY study. J Bone Miner Res 20:1813–1819PubMedCrossRef

Sanders KM, Nicholson GC, Watts JJ et al (2006) Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost-effective? Bone 38:694–700PubMedCrossRef

America’s bone health: The state of osteoporosis and low bone mass in our nation (2002) National Osteoporosis Foundation, Washington, DC

Bone Health and Osteoporosis (2004) U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group (1994) World Health Organ Tech Rep Ser 843:1–129

Prevention and Management of Osteoporosis (2003) Geneva: World Health Organization, Technical Report Series, Vol. 921

10.

Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis (1998) WHO Technical Bulletin: World Health Organization

11.

Miller PD, Barlas S, Brenneman SK et al (2004) An approach to identifying osteopenic women at increased short-term risk of fracture. Arch Intern Med 164:1113–1120PubMedCrossRef

12.

Physician’s Guide to Prevention and Treatment of Osteoporosis (2003) National Osteoporosis Foundation, Washington, DC

13.

Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef

14.

Kanis JA, Oden A, Johnell O et al (2002) Uncertain future of trials in osteoporosis. Osteoporos Int 13:443–449PubMedCrossRef

15.

Fogelman I, Ribot C, Smith R et al (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85:1895–1900PubMedCrossRef

16.

McClung MR, Bensen WG, Bolognese MA et al (1998) Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass. Osteoporos Int 8:111

17.

Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRef

18.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef

19.

Kanis JA, Johnell O, Black DM et al (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:293–300PubMedCrossRef

20.

Quandt SA, Thompson DE, Schneider DL et al (2005) Effect of alendronate on vertebral fracture risk in women with bone mineral density T-score from −1.6 to −.2.6 at the femoral neck: The Fracture intervention trial. Mayo Clin Proc 80:343–349PubMedCrossRef

21.

Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef

22.

Roux C, Seeman E, Eastell R et al (2004) Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20:433–439PubMedCrossRef

23.

Harrington JT, Ste-Marie LG, Brandi ML et al (2004) Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 74:129–135PubMedCrossRef

24.

Heaney RP, Zizic TM, Fogelman I et al (2002) Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int 13:501–505PubMedCrossRef

25.

Black D, Thompson D, Quandt S et al (2002) Alendronate reduces risk of vertebral fracture in women with BMD t-scores above −2.5: results from the Fracture Intervention Trial (FIT). J Bone Miner Res 17:S474

26.

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRef

27.

McCloskey EV, Beneton M, Charlesworth D et al (2007) Clodronate reduces the incidence of fractures in community-dewlling elderly women unselected for osteoporosis: Results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135–141PubMedCrossRef

28.

Dufresne TE, Chmielewski PA, Manhart MD et al (2003) Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73:423–432PubMedCrossRef

29.

Borah B, Dufresne TE, Chmielewski PA et al (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736–746PubMedCrossRef

30.

Borah B, Dufresne TE, Chmielewski PA et al (2002) Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res 17:1139–1147PubMedCrossRef

31.

Borah B, Ritman EL, Dufresne TE et al (2004) Sustained effect of risedronate on trabecular architecture and mineralization over 5 years of treatment: triple biopsy studies by micro-CT. European Symposium on Calcified Tissues, Nice, France, June 5–9

32.

Kanis JA, Johnell O, Oden A et al (2001) Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporosis Int 12:989–995CrossRef

Title: Effects of risedronate on fracture risk in postmenopausal women with osteopenia
Authors: E. S. Siris
J. A. Simon
I. P. Barton
M. R. McClung
A. Grauer
Publication date: 01-05-2008
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 5/2008
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-007-0493-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effects of risedronate on fracture risk in postmenopausal women with osteopenia

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2008

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis

Relationships between fat and bone

Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

Seasonal variation of serum α- and β-cryptoxanthin and 25-OH-vitamin D3 in women with osteoporosis

Association of increased active PTH(1–84) fraction with decreased GFR and serum Ca in predialysis CRF patients: modulation by serum 25-OH-D

Rate and circumstances of clinical vertebral fractures in older men